A Dual Channel Supraglottic Airway Device (LMA Gastro) for Oxygenation in Patients Undergoing ERCP
Not Applicable
Completed
- Conditions
- Gallbladder CarcinomaPancreatic Ductal AdenocarcinomaBile Duct Carcinoma
- Interventions
- Procedure: Endoscopic Retrograde Cholangiopancreatography
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 66
- Registration Number
- NCT04740164
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Minimal Residual Disease Assessment in Patients with Colorectal Cancer, the MiRDA-C Study
Recruiting
- Conditions
- Colorectal AdenocarcinomaStage I Colorectal Cancer AJCC V8Stage II Colorectal Cancer AJCC V8Stage IIA Colorectal Cancer AJCC V8Stage IIB Colorectal Cancer AJCC V8Stage IIC Colorectal Cancer AJCC V8Stage III Colorectal Cancer AJCC V8Stage IIIA Colorectal Cancer AJCC V8Stage IIIB Colorectal Cancer AJCC V8Stage IIIC Colorectal Cancer AJCC V8
- Interventions
- Procedure: Biospecimen CollectionOther: Electronic Health Record Review
- First Posted Date
- 2021-02-04
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 1000
- Registration Number
- NCT04739072
- Locations
- 🇺🇸
Banner - MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Baptist- MD Anderson Cancer Center, Jacksonville, Florida, United States
🇺🇸The Queen's Medical Center, Honolulu, Hawaii, United States
Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Phase 1
Recruiting
- Conditions
- Recurrent Myelodysplastic SyndromeChronic Myelomonocytic Leukemia-2Myelodysplastic SyndromeChronic Myelomonocytic Leukemia-1Recurrent Chronic Myelomonocytic LeukemiaChronic Myelomonocytic Leukemia-0
- Interventions
- First Posted Date
- 2021-02-02
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 44
- Registration Number
- NCT04734990
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders
Phase 2
Active, not recruiting
- Conditions
- Metastatic Small Intestinal AdenocarcinomaStage IV Colorectal Cancer AJCC v8Stage IV Small Intestinal Adenocarcinoma AJCC v8Stage IVB Colorectal Cancer AJCC v8Metastatic Colorectal AdenocarcinomaStage IVC Colorectal Cancer AJCC v8Stage IVA Colorectal Cancer AJCC v8
- Interventions
- Procedure: BiopsyProcedure: Fecal Microbiota TransplantationDrug: Fecal Microbiota Transplantation CapsuleDrug: MetronidazoleDrug: NeomycinBiological: NivolumabBiological: PembrolizumabOther: Questionnaire AdministrationDrug: Vancomycin
- First Posted Date
- 2021-01-28
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT04729322
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial
Phase 1
Recruiting
- Conditions
- Extensive Stage Lung Small Cell CarcinomaStage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8
- Interventions
- First Posted Date
- 2021-01-28
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 63
- Registration Number
- NCT04728230
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL
Phase 1
Terminated
- Conditions
- Metastatic Malignant Solid NeoplasmUnresectable Malignant Solid NeoplasmAdvanced Malignant Solid Neoplasm
- Interventions
- Biological: Anti-TGF-beta Monoclonal Antibody SAR-439459Biological: Cemiplimab
- First Posted Date
- 2021-01-28
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT04729725
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Establishing a Tumor Registry for Patients With Neuroendocrine Carcinoma of the Cervix
Recruiting
- Conditions
- Cervical Large Cell Neuroendocrine CarcinomaStage IB Cervical Cancer AJCC v8Stage IIIB Cervical Cancer AJCC v8Stage IVA Cervical Cancer AJCC v8Cervical Undifferentiated CarcinomaStage IA Cervical Cancer AJCC v8Stage IA2 Cervical Cancer AJCC v8Stage IB1 Cervical Cancer AJCC v8Stage II Cervical Cancer AJCC v8Stage IIB Cervical Cancer AJCC v8
- Interventions
- Other: Follow-UpOther: Medical Chart Review
- First Posted Date
- 2021-01-25
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 750
- Registration Number
- NCT04723095
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer
Phase 2
Recruiting
- Conditions
- Resectable Hepatocellular CarcinomaStage I Hepatocellular Carcinoma AJCC V8Stage IA Hepatocellular Carcinoma AJCC V8Stage IB Hepatocellular Carcinoma AJCC V8Stage II Hepatocellular Carcinoma AJCC V8
- Interventions
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT04721132
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients
Phase 2
Recruiting
- Conditions
- Hematopoietic and Lymphoid Cell NeoplasmInfluenza
- Interventions
- First Posted Date
- 2021-01-15
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT04712539
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma
Phase 1
Active, not recruiting
- Conditions
- Locally Advanced Intrahepatic CholangiocarcinomaMetastatic Intrahepatic CholangiocarcinomaStage III Intrahepatic Cholangiocarcinoma AJCC v8Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
- Interventions
- First Posted Date
- 2021-01-13
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT04708067
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath